Home > A. Molecular pathology > Targeted therapy > Small molecules > larotrectinib
larotrectinib
Friday 8 November 2019
| WKP |
Larotrectinib (tradename Vitrakvi) is an inhibitor of tropomyosin kinase receptors NTRKs TrkA , TrkB , and TrkC. It was discovered by Array BioPharma and licensed to Loxo Oncology in 2013.
